Biogen Inc’s Revenue by Segment (2016-2022)

You need Pro Plan to access KPI data.

Get 60% off on Pro

Discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

About

This statistic highlights Biogen Inc’s Revenue by Segmen, split between Product, anti-CD20 therapeutic programs and other segments, reported on a quarterly basis from Q1 2016 onwards.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information

Subscribe to Pro or Enterprise plans to unlock this feature.

Contact the Analyst

Subscribe to Pro or Enterprise plans to unlock this feature.

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Biogen Inc’s Revenue by Segmen, split between Product, anti-CD20 therapeutic programs and other segments, reported on a quarterly basis from Q1 2016 onwards.

Product, net: Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer’s disease; and FUMADERM for the treatment of acute plaque psoriasis.

Revenue from anti-CD20 therapeutic programs: is referred to as RITUXAN and RITUXAN HYCELA collectively as RITUXAN.

Other Revenue: Revenue earned from collaborations and other relationships, technical development agreements, manufacturing services agreements, and royalty revenue on biosimilar products with Samsung Bioepis.

Biogen Inc’s Revenue by Segment

Revenue by Segment Q3 2020 Q2 2021 Q3 2021 Revenue contribution in Q3 2021
Product, Net $2.69 $2.24 $2.21 79%
Revenue from Anti-CD20 therapeutic programs $0.56 $0.44 $0.16 15%
Other Revenue $0.13 $0.10 $0.16 6%
Total $3.38 $2.78 $2.78 100%

Product, net: The revenue generated from the product net was $2.206 billion in Q3 2021. It showed a decline of around 18% on a  year-on-year basis from $2.690 billion in Q3 2020. This segment contributed 79% of the total revenue of Q3 2021.(All the figures are in billions, except percentages)

Revenue from Anti-CD20 therapeutic programs: This program has earned $0.415 billion in Q3 2021 which on a year-on-year basis showed a decline of 26% from $0.560 billion in Q3 2020. It contributes to 15% of the total revenue of Q3 2021.

Other revenues: Revenue from other sources such as royalties and collaborations have earned a total of $0.158 billion (or $ 518 million approximate) in Q3 2021, which is a 26% growth from $0.126 billion (or $126 million, approximate) in Q3 2020. This also constitutes 6% of the total revenue generated in Q3 2021.

About the Company  

Biogen Inc. was founded by several prominent biologists in Geneva-Walter Gilbert, Kenneth Murray, and Heinz Schaller. It is a Biotechnology pharmaceutical company, with its core growth areas being Immunology, Neuropathic pain, and Acute Neurology. It is solving problems with its products like TECFIDERA, and TYSABRI, treating several neuropathic diseases like relapsing MS and primary progressive MS and ADUHELM for treating Alzheimer’s disease and other potential anti-CD20 therapies with self-research and development and other collaboration agreements.

Did you like Biogen Inc’s Revenue by Segment statistic?

Access more such KPI (key performance indicator) data points, on thousands of US stocks, with Business Quant.

You can get started here.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount until September 30

Pro

$19
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Billed annually, local taxes extra. 

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount on Annual plan

Pro

$49
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.